BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Svensson J, Hagmarker L, Magnander T, Wängberg B, Bernhardt P. Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. EJNMMI Phys 2016;3:15. [PMID: 27491429 DOI: 10.1186/s40658-016-0153-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate 177 Lu-Lilotomab Satetraxetan. J Nucl Med 2018;59:704-10. [DOI: 10.2967/jnumed.117.195347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Thakral P, Sen I, Pant V, Gupta SK, Dureja S, Kumari J, Kumar S, Un P, Malasani V. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM). Br J Radiol 2018;91:20170172. [PMID: 30028180 DOI: 10.1259/bjr.20170172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
3 Kelly VJ, Wu ST, Gottumukkala V, Coelho R, Palmer K, Nair S, Erick T, Puri R, Ilovich O, Mukherjee P. Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer. Theranostics 2020;10:6946-58. [PMID: 32550914 DOI: 10.7150/thno.38236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Xu L, Meng Q, Yao X, Yang R, Zhang P, Li R, Wang F. Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China. Appl Radiat Isot 2022;179:109975. [PMID: 34741954 DOI: 10.1016/j.apradiso.2021.109975] [Reference Citation Analysis]
5 Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, Gjertsson P, Bernhardt P. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. J Nucl Med 2019;60:1406-13. [PMID: 30902877 DOI: 10.2967/jnumed.118.225235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
6 O'Neill E, Kersemans V, Allen PD, Terry SYA, Torres JB, Mosley M, Smart S, Lee BQ, Falzone N, Vallis KA, Konijnenberg MW, de Jong M, Nonnekens J, Cornelissen B. Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy. J Nucl Med 2020;61:743-50. [PMID: 31757844 DOI: 10.2967/jnumed.119.232934] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Araz M, Baltacioglu MH, Saglam S, Ozguven MA, Kucuk NO. Gallbladder Uptake Mimicking Liver Metastasis on 177Lu-DOTATATE Posttherapy Scan Gallbladder Uptake on 177Lu-DOTATATE Scan. Clin Nucl Med 2021;46:e154-5. [PMID: 33512839 DOI: 10.1097/RLU.0000000000003475] [Reference Citation Analysis]
8 Broqueza J, Prabaharan CB, Allen KJH, Jiao R, Fisher DR, Dickinson R, MacDonald-Dickinson V, Uppalapati M, Dadachova E. Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models. Pharmaceuticals (Basel) 2021;15:10. [PMID: 35056067 DOI: 10.3390/ph15010010] [Reference Citation Analysis]
9 Okamoto S, Shiga T, Tamaki N. Clinical Perspectives of Theranostics. Molecules 2021;26:2232. [PMID: 33924345 DOI: 10.3390/molecules26082232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
11 Minczeles NS, de Herder WW, Konijnenberg MW, Feelders RA, Brabander T, Hofland J. Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004203] [Reference Citation Analysis]
12 Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 2018;45:2426-41. [PMID: 29785514 DOI: 10.1007/s00259-018-4044-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
13 Graves SA, Hobbs RF. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Semin Radiat Oncol 2021;31:37-44. [PMID: 33246635 DOI: 10.1016/j.semradonc.2020.07.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose Mapping After Endoradiotherapy with 177 Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. J Nucl Med 2018;59:75-81. [DOI: 10.2967/jnumed.117.193706] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
15 Mora-Ramirez E, Santoro L, Cassol E, Ocampo-Ramos JC, Clayton N, Kayal G, Chouaf S, Trauchessec D, Pouget JP, Kotzki PO, Deshayes E, Bardiès M. Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys 2020;47:4602-15. [PMID: 32632928 DOI: 10.1002/mp.14375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Aboagye EO, Kraeber-Bodéré F. Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine". Eur J Nucl Med Mol Imaging 2017;44:1559-74. [PMID: 28597119 DOI: 10.1007/s00259-017-3704-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
17 Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging 2018;45:1233-41. [PMID: 29470615 DOI: 10.1007/s00259-018-3964-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
18 Roth D, Gustafsson J, Sundlöv A, Sjögreen Gleisner K. A method for tumor dosimetry based on hybrid planar-SPECT/CT images and semiautomatic segmentation. Med Phys 2018;45:5004-18. [PMID: 30199102 DOI: 10.1002/mp.13178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. J Nucl Med 2018;59:1699-705. [PMID: 29653971 DOI: 10.2967/jnumed.118.209841] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]